Taking aim at Medicaid misclassifications like Mylan's EpiPen, senators look to end a 'pharma ripoff'

5th December 2018 Uncategorised 0

Two senators introduced a bill cracking down on drug misclassifications that cost Medicaid—and taxpayers—millions in underpaid rebates. In some cases, the rebates reach hundreds of millions: Mylan, for one, agreed to pay $465 million to settle allegations that it shorted Medicaid by calling EpiPen a generic.

More: Taking aim at Medicaid misclassifications like Mylan's EpiPen, senators look to end a 'pharma ripoff'
Source: fierce